《大行報告》裏昂下調思摩爾(06969.HK)目標價至35元 評級「買入」
裏昂發表報告指,由於市場情緒的轉變、監管因素和可能出現的競爭,思摩爾(06969.HK)股價在過去一個月累跌42%。該行維持「買入」評級,因爲看好其下半年和中期前景,加上估值具吸引力。惟由於情緒和政策風險的變化,將目標價從59元下調至35元。
裏昂指,有媒體猜測思摩爾將失去其對客戶FEELM技術的唯一供應商地位。管理層澄清指擁有FEELM的專利保護,並與主要客戶簽訂獨家供應關係。該行預計思摩爾能夠憑藉強勁的研發能力和質量,維持核心客戶的強大黏性。在政策方面,管理層預計內地的監管框架將在2022年落地,美國的菸草產品預上市申請(PMTA)審查過程將在今年加快。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.